Inventory consisted of the following (in thousands):

Accrued and other liabilities consisted of the following (in thousands):


	June 30, 2024		December 31, 2023
Clinical studies	$	16,766	$	15,744
Professional fees	6,091		5,911
Short-term lease liability	6,062		5,943
Deferred revenue	5,852		4,748
Contingent consideration	4,743		5,469
Laboratory processing fees and materials	3,431		2,890
Deferred payments for intangible assets	818		920
Travel and expenses	767		—
Accrued shipping expenses	487		335
Capital expenditures	235		151
Accrued royalty	222		348
License and other collaboration fees	—		250
Other accrued expenses	1,979		2,788
Total accrued and other liabilities	$	47,453	$	45,497